Immunovant's FcRn inhibitor batoclimab just struck out in two Phase 3 trials for thyroid eye disease, sending shares tumbling and raising hard questions about whether this entire drug class can crack TED. The company is betting its future on a next-gen molecule, but the clock is ticking.
Imagine training for a marathon for three years, then tripping at mile 25.
That's roughly what happened to Immunovant on April 2, when its FcRn inhibitor batoclimab failed not one but two Phase 3 trials in thyroid eye disease (TED). The stock dropped over 8% before most people had finished their morning coffee, and the company is now scrambling to figure out what comes next for a drug it once pinned major hopes on.
The failure isn't just a bad day for Immunovant. It reshapes the entire competitive landscape for one of biotech's hottest drug classes.
What Even Is an FcRn Inhibitor?
Before we get into the wreckage, a quick primer. Your body recycles antibodies through a receptor called FcRn (neonatal Fc receptor). Think of FcRn as a recycling bin that keeps antibodies circulating in your blood longer than they otherwise would. That's great when you need protection from infections. It's terrible when those antibodies are the ones attacking your own body.
FcRn inhibitors block this recycling process, essentially sending pathogenic antibodies to the trash instead of putting them back into circulation. The concept is elegant, and it's already working in other diseases. Argenx's Vyvgart, the class leader, has been approved for myasthenia gravis (a neuromuscular disease) and is expanding into new territories.
Thyroid eye disease was supposed to be the next big frontier. TED is an autoimmune condition where rogue antibodies cause the tissue behind your eyes to swell, leading to bulging eyes, double vision, and in severe cases, vision loss. Right now, only one immunotherapy is FDA-approved for TED: teprotumumab (brand name Tepezza), which works through a completely different mechanism. But Tepezza has relapse concerns and side effects, particularly hearing problems. That left a door wide open for FcRn inhibitors to walk through.
Batoclimab just walked face-first into the door frame.
A Design That May Have Sabotaged Itself
The two Phase 3 trials (collectively called the GO studies) tested subcutaneous batoclimab in patients with active, moderate-to-severe TED. The primary endpoint was straightforward: the proportion of patients who achieved at least a 2 millimeter reduction in proptosis (the medical term for eye bulging) at Week 24.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Both studies missed that target.
But the details are where it gets interesting, and where Immunovant might argue the design let them down. The dosing regimen involved 12 weeks of high-dose batoclimab followed by 12 weeks at a lower dose. The data showed greater improvement during the high-dose period than during the low-dose maintenance phase. In plain English: the drug seemed to work better when patients got more of it, and the benefits faded when the dose dropped.
That's a tantalizing clue. It suggests the drug might actually do something meaningful if you keep the dose high, but the trial wasn't designed to test that. The primary endpoint was measured after both phases combined, and by Week 24, the low-dose period had apparently diluted whatever gains the high-dose period produced.
It's like testing whether a car can drive 200 miles on a full tank, but switching to fumes halfway through. Of course you're not going to make it.
The Silver Lining Is Pretty Thin
Immovant pointed to a few bright spots in the wreckage. In hyperthyroid TED patients (those whose thyroid is still overactive), batoclimab normalized thyroid hormone levels at rates comparable to what was seen in a previous Phase 2 study in Graves' disease, the autoimmune thyroid condition that typically precedes TED. Safety was also consistent with prior data, with no new signals popping up.
Those findings are scientifically interesting. But "the drug didn't hurt anyone and it might help your thyroid" is a tough pitch when you just blew two Phase 3 trials in the indication you were actually targeting. The safety profile keeps the door open for the drug's future, but nobody's celebrating.
A Crowded Class Gets One Less Competitor
The FcRn inhibitor market is a roughly $2.2 to $2.4 billion business in 2025, projected to hit $3.4 billion by 2035. And it is fiercely competitive.
Argenx sits on top like a Lannister on the Iron Throne, commanding roughly 65 to 69% market share with efgartigimod (Vyvgart). The company has been methodically expanding into neurology, dermatology, and hematology. Johnson & Johnson's nipocalimab (brand name Imaavy) is emerging as a credible challenger, focusing on pricing agility and geographic expansion. UCB's rozanolixizumab (Rystiggo) is pushing into neurological indications.
Batoclimab's failure effectively removes one horse from the TED race. Viridian Therapeutics, which has been developing IGF-1R inhibitors (VRDN-001 and VRDN-003) specifically for TED, also benefits from having one fewer competitor in the field.
For Immunovant, the calculus is more sobering. The company was already a mid-tier player in the FcRn space, and losing its most advanced ophthalmology program narrows the pipeline at a time when investors want to see breadth.
Immunovant's Plan B: Meet IMVT-1402
The company isn't folding. Far from it. Immunovant is pivoting hard toward IMVT-1402, its next-generation FcRn inhibitor, which it calls the future of its pipeline.
IMVT-1402 is being developed across multiple autoimmune diseases, with Graves' disease as the top priority. Topline data from a potentially registrational Phase 2b study in Graves' disease are expected in 2027. There's also a Phase 3 study underway in chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve condition where the immune system attacks the protective coating around nerves.
The Graves' disease angle is particularly clever. The failed TED trials actually generated useful Graves' data as a byproduct (since Graves' disease often causes TED), giving Immunovant a head start on understanding how its FcRn approach works in that broader patient population. It's like losing the battle but stealing the enemy's playbook on the way out.
As for batoclimab itself, Immunovant isn't killing it outright. The company says it will review the drug's future with its Korean partner HanAll Biopharma and provide a joint update. Translation: they're not ready to pull the plug, but nobody should expect a major batoclimab comeback anytime soon.
What Wall Street Thinks (and What It Doesn't Know Yet)
The 8.12% stock drop was swift but not catastrophic. Shares were trading in a range of $25.84 to $27.54 on the day, with a 52-week range stretching from $12.72 to $29.25. Before the failure, nine analysts had a consensus "Buy" rating with an average price target of $30.78. At least one analyst downgraded from "Strong Buy" to "Buy" in the aftermath, citing the need to refocus expectations on IMVT-1402.
The relatively measured selloff suggests the market had already partially priced in the risk. Interest in batoclimab for TED had been "waning," as one source noted, and argenx had previously discontinued its own FcRn inhibitor Vyvgart in TED (a detail that should have been a warning sign for the whole approach in this indication).
The bigger question is whether IMVT-1402 can carry the entire company. Immunovant has no products on the market generating revenue. It's burning cash. And its pipeline now hinges heavily on a next-gen drug that won't produce registrational data until 2027 at the earliest. Community fair value estimates have pegged the stock as high as $41.13, but those assumed trial success and adequate funding, neither of which is guaranteed.
The Bigger Picture: Is TED Just Hard for FcRn Inhibitors?
Zoom out from Immunovant for a moment. This failure raises an uncomfortable question for the entire FcRn inhibitor class in eye disease. If batoclimab couldn't hit its endpoint, and argenx previously walked away from Vyvgart in TED, maybe the problem isn't the specific drugs. Maybe FcRn inhibition alone isn't enough for this particular disease.
TED involves complex inflammatory processes beyond just antibody-driven damage. Reducing circulating IgG (the type of antibody FcRn inhibitors target) is helpful, but it might not address the full cascade of tissue remodeling and inflammation happening behind the eye. Teprotumumab works through a different pathway entirely (IGF-1R inhibition), which may be why it succeeded where antibody-lowering approaches have struggled.
Argenx's own Phase 3 UplighTED trial in TED was discontinued in December 2025 for futility based on an interim analysis, further undermining the thesis that FcRn inhibitors can crack TED. That thesis may now be dead for a generation.
The Bottom Line
Immovant bet big on batoclimab in TED and lost. The dosing design may have been partly to blame, offering a frustrating "what if" that will haunt the team for years. But the company still has cards to play: IMVT-1402 in Graves' disease and CIDP, a clean safety profile to build on, and Roivant's backing as majority shareholder.
The next 18 months will determine whether this was a painful detour or a fatal blow. IMVT-1402's Graves' data in 2027 is now, for all practical purposes, the company's make-or-break moment. No pressure.
4 min read
Another $100M Bet That You'll Ditch the Needle for a Pill
A Boulder, Colorado biotech you've never heard of just raised $100 million without testing its drug in a single person. Ambrosia Biosciences is betting its oral GLP-1 pill can compete in the most crowded race in pharma, and investors are lining up to fund that bet.
